How rapidly should remission be achieved?

Digestive Diseases

Volumn 28, Issue 3, 2010, Pages 548-555

  Isaacs, Kim L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammatory bowel disease; Mucosal healing; Remission

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; 6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; NATALIZUMAB; SALAZOSULFAPYRIDINE;

CONFERENCE PAPER; CROHN DISEASE; HUMAN; MUCOSAL NECROSIS; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INTESTINAL MUCOSA; REMISSION INDUCTION; WOUND HEALING;

EID: 77957861830     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320415     Document Type: Conference Paper

References (55)

1. Lichtenstein G, Yan S, Bala M, Hanauer S: Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastro-enterol 20 04; 99: 91-9 6.
2. Reilly M, Gerlier L, Brabant Y, Brown M: Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008; 30:393-404.
3. Best W, Becktel J, Singleton J, Kern F: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterolog y 1976; 70: 439-444.
4. Greenberg G, Feagan B, Martin F, Sutherland L, et al: Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 836-841.
5. Rutgeerts P, Löfberg R, Malchow H, Lamers C, et al: A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-845.
6. Sandborn W, Feagan B, Lichtenstein G: Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007; 26: 987-1003.
7. Summers R, Switz D, Sessions J, Becktel J, et al: National Cooperative Crohn's Disease Study: results of drug treatment. Gastroen-terology 2010; 77:847-869.
8. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pet-tersson E: A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998; 339:370-374.
9. Present D, Korelitz B, Wisch N, Glass J, et al: Treatment of Crohn's disease with 6-mercap-topurine: a long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-987.
10. Sandborn W,Tremaine W,Wolf D,Targan S,et al., Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease, North American Azathioprine Study Group. Gas-troenterology, 1999, 117, 527-535.
11. Feagan B, Rochon J, Fedorak R, Irvine E, et al: Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292-297.
12. Targan S, Hanauer S, van Deventer S, Mayer L, et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035.
13. Hanauer SB, Sandborn WJ, Rutgeerts P, Fe-dorak RN, Lukas M, MacIntosh D, Panac-cione R, Wolf D, Pollack P: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLAS-SIC-I trial. Gastroenterology 2006; 130: 323-333.
14. Sandborn W, Feagan B, Stoinov S, Honiball P, et al: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238.
15. Sandborn W, Colombel J, Enns R, Feagan B, et al: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 3538: 1912-1925.
16. Targa n S, Feaga n B, Fedora k R, L ashner B, et al: Natalizumab induction and maintenance therapy for Crohn's disease, Gastroenterol-ogy, 2007, 132:, 1672-1683.
17. Truelove S, Witts L, Tunbridge R, Watkinson G, et al: Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ 1955; 2: 1041-1048.
18. Powell-Tuck J, Day D, Buckell N, Wadsworth J, et al: Correlations between defined sig-moidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533-537.
19. Lichtiger S, Present D, Kornbluth A, Gelernt I, et a l: Cyclosporine in severeu lcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-1845.
20. Schroeder K, Tremaine W, Ilstrup D: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987; 317:1625-1629.
21. Sutherland L, Martin F, Greer S, Robinson M, et al: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, procto-sigmoiditis, and proctitis. Gastroenterology 1987; 32:1894-1898.
22. Baron J, Connell A, Lennard-Jones J: Variation between observers in describing muco-sal appearances in proctocolitis. BMJ 1964; 1: 89-92.
23. Rachmilewitz D: Coated mesalazine (5-ami-nosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised tria l. BMJ 1989; 298: 82-86.
24. Baro J, Connell A, Kanaghinis T, Lennard-Jones J, et al: Out-patient treatment of ulcer-ative colitis: comparison between three doses of oral prednisone. BMJ 1962; 2: 441-443.
25. Kjeldsen J: Treatment of ulcerative colitis with high doses of oral prednisolone: the rate of remission, the need for surgery, and the effect of prolonging the treatment. Scand J Gastroenterol 1993; 28: 821-826.
26. Jewell D, Truelove S: Azathioprine in ulcer-ative colitis: final report on controlled therapeutic tria l. BMJ 1974; 4: 627-630.
27. Van Assche G, D'Haens G, Noman M, Ver-meire S, et al: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125:1025-1031.
28. Weber A, Fein F, Koch S, Dupont-Gossa r t A, et al: Treatment of ulcerative colitis refractory to steroid therapy by oral microemul-sion cyclosporine (Neoral). Inflamm Bowel Dis 2006; 12:1131-1135.
29. Rut geer ts P, Sa ndborn W, Feagan B, Rein is ch W, et al: Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 2005, 353, 2462-2476.
30. Su C, Lichtenstein G, Krok K, Brensinger C, et al: A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004; 126: 1257-1269.
31. Modigliani R, Mary J, Simon J, Cortot A, et al: Clinical, biological, and endoscopic picture of attacks of Crohn's disease: evolution on prednisolone. Groupe d'Etude Thérapeu-tique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98:811-818.
32. van Dullemen H, van Deventer S, Hommes D, Bijl H, et al: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterol-ogy 1995; 109:129-135.
33. Baert F, Moortgat L, Van Assche G, Caene-peel P, et al: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-468.
34. Frøslie K, Jahnsen J, Moum B, Vatn M, et al: Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422.
35. Mantzaris G, Christidou A, Sfakianakis M, Roussos A, et al: Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inf lamm Bowel Dis 2009; 15: 375-382.
36. Allez M, Lemann M, Bonnet J, Cattan P, et a l: Long term outcome of patients w it h active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gas-troenterol 2002; 97:947-953.
37. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, et al: Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990 ; 99: 956-963.
38. Wright R, Truelove S: Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Dig Dis Sci 1966; 11:847-857.
39. Sandborn W, Colombel J, Reinisch W, Fea-gan B, et al: Infliximab induces and maintains mucosal healing in ulcerative colitis patients: the ACT trials. Am J Gastroenterol 2005; 100:S310.
40. Røseth A, Schmidt P, Fagerhol M: Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gas-troenterol 1999; 34: 50-54.
41. Tibble J, Sigthorsson G, Bridger S, Fagerhol M, et al: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119:15-22.
42. Gisbert J, McNicholl A, Gomollon F: Questions and answers on the role of fecal lacto-ferrin as a biological marker in inflammatory bowel disease. Inf lamm Bowel Dis 2009; 15:1746-1754.
43. Ruffolo C, Scarpa M, Faggian D, Basso D, et al: Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire. J Gastrointest Surg 2010; 14 : 24-31.
44. Efthymiou A, Viazis N, Mantzaris G, et al: Does clinical response correlate with muco-sal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. In-flamm Bowel Dis 2008;14:1542-1547.
45. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel J: Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7:15-29.
46. Kruis W, Kiudelis G, Rácz I, Gorelov I, et al: Once daily versus three times daily mesala-zine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58: 233-240.
47. Sandborn W, Van Os E, Zins B, Tremaine W, et al: An intravenous loading dose of azathi-oprine decreases the time to response in patients with Crohn's disease. Gastroenterolo-gy 1995; 109:1808-1817.
48. Kozarek R, Patterson D, Gelfand M, Boto-man V, et al: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 11 0 : 353-356.
49. Mañosa M, Naves J, Leal C, Cabré E, et al: Does methotrexate induce mucosal healing in Crohn's disease? Inflamm Bowel Dis 2009; 16 : 377-378.
50. van Dullemen H, van Deventer S, Hommes D, Bijl H, et al: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterol-ogy 1995; 109:129-135.
51. Rutgeerts P, Diamond R, Bala M, Olson A, et al: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest En-dosc 2006; 63:433-442.
52. Sandborn W, Rutgeerts P, Reinisch W, Mantzaris G, et al: SONIC: a randomized, double-blind, controlled trial comparing in-fliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflamm Bowel Dis 2008; 142 : S1.
53. Rutgeerts P, D'Haens G, Van Assche G, Sandborn W, et al: Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease: first results of the extend trial. Gastro-enterology 2009; 136(suppl 1):A116.
54. Colombel J, Hebuterne X: Endoscopic mu-cosal improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the music clinical trial. Am J Gastroenterol 2009; 103:S432.
55. Rutgeerts P, Allison M, Cortot A, D'Haens G, et al: Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-I). Gastroenterology 2004; 126(suppl 2):A208.